Epocrates vs Micromedex: cost, app access and which drug reference to use

Only one side of this comparison has a price you can read. Epocrates is free to install and the free tier has no expiry. The paid tier, epocrates+, is an in-app purchase listed at $179.99 a year or $24.99 a month on the US App Store, which we re-read in September 2026. Over twelve months the monthly plan costs $299.88, so anyone who keeps it past seven months should switch to annual. The App Store also shows older in-app items under the Epocrates Plus name at other prices; those are legacy listings, and the two epocrates+ figures are the ones a new subscriber pays. We track the Epocrates side in more detail on the Epocrates cost page.

Merative publishes nothing. We checked the Micromedex product page and the clinical decision support pricing page again in September 2026: neither carries a dollar figure, and both end at a contact form. Micromedex is quoted per organization on the number of users, the modules licensed (drug reference, IV compatibility, NeoFax, toxicology, RED BOOK drug pricing) and the contract term. You will find confident monthly figures for Micromedex on software directory sites. They are not vendor-published, they disagree with each other, and we do not repeat them. Our fuller look at why is in Micromedex subscription cost.

So the real comparison for an individual clinician is not $179.99 against some Micromedex number. It is $0 or $179.99 for Epocrates against $0 for Micromedex when your employer pays, and no price at all when it does not. That is why the useful question on this page is access, not cost.

Not in any practical way. The Micromedex app is a free download, but it does nothing until it is activated. Merative's App Store instructions are explicit: open the app, it shows an activation code and link, and you complete activation by signing in with your Micromedex credentials or by visiting micromedexsolutions.com/activate from the desktop version your institution provides. The device has to stay online to activate, and Merative suggests doing it on your facility Wi-Fi. There is no in-app purchase and no personal plan on the store listing.

The older standalone apps, Micromedex Drug Reference and Micromedex Drug Interactions, are no longer supported; Merative moved users to the single Micromedex app, which now carries the drug reference summary, NeoFax and pediatric content, IV compatibility, drug interactions, calculators and the Micromedex Assistant. If a colleague tells you they bought Micromedex on their phone years ago, that route is gone.

In practice this decides the comparison for three groups. A clinician in a health system that licenses Micromedex already has it and should use it. A clinician in private practice, locum work or an outpatient group without an institutional contract cannot get it, and Epocrates, a personal Lexidrug subscription or Clinical Pharmacology are the realistic choices. A clinician about to leave a hospital loses Micromedex on the last day and should set up a personal reference before then, not after. If your practice is weighing a group contract instead, the thresholds that push you from individual to organizational pricing are covered in our institutional licensing guide.

Micromedex, without much argument. IV compatibility is inside the Micromedex app and Merative sells IV compatibility tools as a separate offering in the Micromedex family, which tells you how central that workflow is to its customers. Toxicology teams are a named audience on Merative's product page, with content for identifying and managing exposures. Epocrates does neither: it has no IV compatibility tool and it is not a toxicology reference. If you mix or hang infusions, or you field poisoning calls, Epocrates is not the right tool for that part of the job, at any price.

That is also the most common reason a clinician with free Epocrates on their phone still opens Micromedex on a workstation. The bedside question about whether two drugs can share a Y-site cannot wait for a second search somewhere else. If you do not have Micromedex, our IV compatibility checker covers common pairs, and we explain how Micromedex organizes its compatibility data in Micromedex IV compatibility. For pharmacy teams choosing between the two big compendia on this point, Lexicomp vs Micromedex goes further.

Both have a multi-drug interaction checker, and both are credible. The difference is depth and reach, not whether the checker works. Epocrates puts its checker on the free tier, which is why it is the one most clinicians actually run in clinic: it is already on the phone and it answers in seconds. Micromedex's interaction content sits inside a database built for pharmacists, with severity, documentation level and management detail that goes further than a quick lookup needs, and it is available wherever your institution has licensed it, including the app.

You will see a 2016 study quoted in forums that scored five interaction programs, Epocrates and Micromedex among them, on accuracy and comprehensiveness. It is a decade old, both products have changed since, and we would not choose between them on it. The more useful test is your own: take five interacting pairs you see every month, run them in both, and compare what each tells you to do. Paying for epocrates+ does not change the interaction checker; the paid tier adds disease content, not better drug data.

Whichever you use, the limitation is the same. An interaction checker answers for the drugs you type in. The interaction that causes harm is usually on a home medication list nobody entered, which is the gap covered in the last section below.

If you work in a hospital that licenses Micromedex, use it for inpatient questions and keep free Epocrates on your phone for everything else. Most residents and hospitalist NPs end up exactly there, and it costs nothing. Whether to pay $179.99 for epocrates+ on top depends on whether you use the disease monographs and lab interpretation away from a workstation; if UpToDate is available through your library, most of that is already covered, and our Epocrates vs UpToDate comparison walks through the overlap.

If you work outside a health system, in a private practice, urgent care group or telehealth company, Micromedex is effectively off the table and the choice is between personal subscriptions. Epocrates free is the floor. Above it, epocrates+ at $179.99 a year adds disease content, a Lexicomp subscription at $29.99 a month adds pharmacy-grade monographs, and Clinical Pharmacology, Elsevier's drug database, lists a 12-month individual plan at $650 with IV compatibility from Trissel's included; we break that one down in Clinical Pharmacology subscription cost. The wider field, role by role, is on our best drug reference app page.

Pharmacists are the exception to all of this. If you verify orders, compound or run an IV room, you need a compendium with IV compatibility and toxicology, and Micromedex or Lexidrug through your employer is the answer. Epocrates is a convenience on your phone, not your reference of record.

Epocrates and Micromedex are both references. You ask, they answer, and the interaction checker in each is a screen you have to remember to open with the right drugs typed in. Prescribing errors cluster where nobody thought to ask: the patient already on a CYP3A4 inhibitor, the creatinine that came back after the order went in, the allergy documented two admissions ago.

Prescriber.io is built for that step rather than for reading. You enter the drug and the patient's scenario once and the card returns interactions across the whole list, contraindications, allergy blockers, renal and hepatic dose adjustments and guideline-based alternatives together, each with a cited source, for a licensed clinician to review and sign. It is priced per clinician per month and it works alongside whichever reference you keep. It does not replace Micromedex's IV compatibility or toxicology depth. If you are replacing a compendium rather than adding to one, our Micromedex alternative page and the Epocrates vs Lexicomp comparison cover the other options.